Targretin | Gel treatment for cutaneous T-cell lymphoma (CTCL) and mycosis fungoides - Bexarotene from Eisai

		Home Contact Us Site Map

About Eisai	Our Products	Research	Eisai Careers	Press Room
Home / Our Products / Oncology Products / Targretin® (bexarotene) gel 1%

Aloxi^® (palonosetron hydrochloride)

DACOGEN^® (decitabine) for Injection

Gliadel^® (polifeprosan 20 with carmustine implant) Wafer

Hexalen^® (altretamine) Capsules

ONTAK® (denileukin diftitox)

Panretin® (alitretinoin) gel 0.1%

Salagen^® (pilocarpine hydrochloride) Tablets

Targretin® (bexarotene) capsules

Targretin® (bexarotene) gel 1%

Targretin® (bexarotene) gel 1%

For more information about this product, please call the Medical Services Dept. at 877-873-4724. If you are a US Healthcare Professional you may also search for more information at www.eisaimedicalinformation.com.

Targretin® (bexarotene) gel 1% (healthcare professional information / patient information)

Printer Friendly Version

$Targretin (bexarotene) gel 1% the topical for cutaneous lesions in patients with CTCL (Stage IA and IB) who have refractory or persistent disease after other therapies or who have not tolerated other therapies$

© Copyright Eisai Inc. 2010 -- 9/2/2010 8:25:21 PM